Anika Therapeutics Inc.

Last updated September 27, 2026

Organization details

Legal name
Anika Therapeutics Inc.
Former names
Anika Research Inc
Ownership
Public
Status
Active
SIC code
3841 — Surgical & Medical Instruments & Apparatus
Jurisdiction of incorporation
Delaware
Headquarters city
Bedford
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
ANIK
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0000898437
EIN
04-3145961

Board of directors

Chief executives

Cheryl R. Blanchard · President, CEO, Director
Dates unknown
Stephen D. Griffin · President and CEO
Dates unknown

Director election results

Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

5 of this board's directors also sit on 9 other boards.

Network of Anika Therapeutics Inc.'s board connections Neuronetics Inc. Neuronetics Inc. Aprea Therapeutics Inc. Aprea Therapeutics Inc... Avient Corporation Avient Corporation Dare Bioscience Inc. Dare Bioscience Inc. Medtronic plc. Medtronic plc. Orthofix Medical Inc. Orthofix Medical Inc. TELA Bio Inc. TELA Bio Inc. Telix Pharmaceuticals Limited Telix Pharmaceuticals... Xilio Therapeutics Inc. Xilio Therapeutics Inc... Cheryl R. Blanchard Cheryl R. Blanchard John B. Henneman III John B. Henneman III Joseph H. Capper Joseph H. Capper Sheryl L. Conley Sheryl L. Conley William R. Jellison William R. Jellison Anika Therapeutics Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$264,298
4 purchases by 3 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Aug 4, 2026 Gary P. Fischetti Director Open-market purchase +1,000 $20.32 $20,315
Aug 3, 2026 Gary P. Fischetti Director Open-market purchase +1,000 $20.75 $20,745
Jun 18, 2026 Gary P. Fischetti Director Grant or award +10,402 — —
Jun 18, 2026 John B. Henneman III Director Grant or award +10,402 — —
Jun 18, 2026 Stephen Richard Director Grant or award +10,402 — —
Jun 18, 2026 Joseph H. Capper Director Grant or award +10,402 — —
Jun 18, 2026 Sheryl L. Conley Director Grant or award +10,402 — —
Jun 3, 2026 Stephen D. Griffin Director, Officer (President and CEO) Option exercise +12,840 — —
Jun 3, 2026 Stephen D. Griffin Director, Officer (President and CEO) Shares withheld for tax −3,769 $14.41 $54,311
May 1, 2026 John B. Henneman III Director Open-market purchase +5,000 $14.66 $73,300
Apr 30, 2026 Stephen D. Griffin Director, Officer (President and CEO) Open-market purchase +12,200 $12.29 $149,938
Mar 15, 2026 Colleran David Officer (EVP, General Counsel, Corp Sec) Option exercise +6,449 — —
Mar 15, 2026 Cheryl R. Blanchard Director Option exercise +25,131 — —
Mar 15, 2026 McLeod Ian Officer (SVP, CAO & Treasurer) Option exercise +2,658 — —
Mar 15, 2026 Colleran David Officer (EVP, General Counsel, Corp Sec) Shares withheld for tax −1,893 $14.20 $26,881

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.